GenFleet Therapeutics-B (02595): First Patient Dosed in China and Overseas for Phase II Study of Pan-RAS Inhibitor GFH276 Combination Therapy in Pancreatic Cancer; Phase II Trial Stage to Encompass Three First-Line Combination Regimens
Zhitong Finance APP News, GenFleet Therapeutics-B (02595) announces that the oral pan-RAS inhibitor GFH276 has entered an Ib/II phase multicenter, open-label combination therapy study, which will be conducted at dozens of research centers in China and Australia. The first overseas enrolled patient recently completed dosing at Monash Health in Australia, and the first Chinese enrolled patient completed dosing in the third quarter of this year at Fudan University Shanghai Cancer Center. The study aims to evaluate the efficacy and safety of multiple combination therapies in treating RAS-mutant pancreatic cancer and advanced solid tumors; the Phase II trial stage will include three first-line pancreatic cancer treatment regimen cohorts, namely GFH276 combined with cetuximab (EGFR monoclonal antibody), GFH276 combined with AG (standard chemotherapy regimen), and GFH276 combined with mFOLFIRINOX (standard chemotherapy regimen).
Latest

